Back
ESC Premium Access

PCSK9 inhibition: what do we know from clinical trials?

Session: PCSK9: Beyond lipid - lowering effects?
Topic: Endothelial function
Speaker: Professor J. Chapman (Paris, FR)
Event: ESC Congress 2017

Congress Presentation

Add to my library

Like

About the speaker

Professor John Chapman

Pitie Salpetriere APHP University Hospital, Paris (France)
17 presentations
0 follower

3 more presentations in this session

State of the Art: PCSK9 - Beyond lipid-lowering effects?

Speaker: Professor U. Landmesser (Berlin, DE)

Access
Slides
Video
Like
Thumbnail

PCSK9 beyond its role in cholesterol homeostasis: co-activator of platelet function

Speaker: Assistant Professor M. Camera (Milan, IT)

Access
Abstract
Slides
Video
Like
Thumbnail

Serum PCSK9 in relation to coronary near-infrared spectroscopy-derived lipid core burden index and long-term cardiovascular outcome [ATHEROREMO-NIRS substudy].

Speaker: Miss S. Anroedh (Rotterdam, NL)

Access
Abstract
Like
Thumbnail

Access the full session

PCSK9: Beyond lipid - lowering effects?

Speakers: Professor J. Chapman, Professor U. Landmesser, Assistant Professor M. Camera, Miss S. Anroedh
Access
Like
Thumbnail

About the event

Image

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources